Abstract Details

Title An Analysis of the Efficacy and Tolerability of Eslicarbazepine Acetate (ESL) by Study Period in Two Phase III Conversion-to-ESL Monotherapy Trials

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 276

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Steve Chung, MD, FAAN (Banner University Medical Center) PRESENTER	The institution of Dr. Chung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ucb pharma. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Life sciences. Dr. Chung has received personal compensation in the range of $500-$4,999 for serving as a Consultant for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for eisai. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for ucb. Dr. Chung has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life sciences. Dr. Chung has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for sunovion.
Amir M. Arain, MD, FAAN (University of Utah)	Dr. Arain has nothing to disclose.
Todd Grinnell, PhD	Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
David Cantu, PhD (Sunovion Pharmaceuticals Inc.)	Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Hailong Cheng	No disclosure on file
	No disclosure on file